Skip to main content
Clinical Trials/CTRI/2021/09/036826
CTRI/2021/09/036826
Suspended
Phase 2

A double blinded randomized controlled clinical study to evaluate the efficacy of the Tulasi Ashwagandhadi Herbal Drops on Oxygen Saturation (SPO2) in the management of COVID-19 affected cases.

Charak Hanf Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
Charak Hanf Pvt Ltd
Status
Suspended
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Charak Hanf Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • Male or female subjects who have been found to be COVID\-19 positive
  • The Oxygen Concentration level (SpO2\) is between 85\-95% observable during baseline screening.
  • Subjects in the age group 18\-65 years (both the ages inclusive).
  • Subjects willing to give a written informed consent and agree to come for a regular follow up visit.
  • Subjects with mild to moderate level of symptoms pertaining to COVID\-19
  • Subjects willing to abide by and comply with the study protocol.
  • Subjects who have not participated in a similar investigation in the past three months.

Exclusion Criteria

  • Subjects who have undergone invasive treatments like surgery or other treatment within 3 months before screening into the study.
  • Subjects having any active disease which may interfere in the study.
  • Any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, severe anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness.
  • Subjects who have taken chemotherapy for cancer in the 6 months prior to start of the study or have a plan to do treatments during study.
  • Subjects (females) who are pregnant or lactating
  • A known history or present condition of allergic response/hypersensitivity to any ingredients and pharmaceutical products.
  • Chronic illness which may influence the respiratory state.
  • Subjects who had been part of any other clinical study within 3 months before screening into the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials